Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology

EMA Recommends 12 New Drugs for Cholesterol, Psoriasis, and Rare Diseases

July 29, 2026 Dr. Michael Lee – Health Editor Health

European health regulators have formally recommended twelve new medications for authorization, including a targeted oral treatment for plaque psoriasis and a sustained-release intraocular implant for chronic eye conditions, marking a significant shift in clinical care options across member states. Announced by the European Medicines Agency (EMA) and detailed by trade and news reporting from agencies including ANSA and Quotidiano Sanità, the July recommendations span rare diseases, metabolic disorders, and infectious disease preventions.

  • Expanded Therapeutic Arsenal: The EMA issued positive opinions for 12 new medicines, targeting conditions ranging from lipid disorders to severe dermatological inflammation.
  • Cardiovascular Innovation: The next-generation CETP inhibitor obicetrapib demonstrated significant LDL-cholesterol reductions of up to 50 percent in clinical development, according to recent updates highlighted by Pharmastar.

Metabolic Therapeutics and Low-Density Lipoprotein Management

Dermatology and Ophthalmology Breakthroughs

The regulatory panel also backed the first oral treatment for moderate-to-severe plaque psoriasis, altering a treatment landscape historically dominated by injectable biologics. Simultaneously, the EMA greenlit an intraocular implant designed to deliver sustained drug release directly to affected ocular tissues, minimizing systemic absorption while managing chronic intraocular inflammation.

Public Health Implications and Vaccine Updates

Beyond chronic disease treatments, the regulatory update encompasses vital adaptations for infectious disease prevention. The agency issued approvals for updated COVID-19 vaccine formulations, aligning public health defenses with epidemiological surveillance data.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Keep reading

  • Win-Win Science and Innovation Driving Development Through the Institute
  • Trump Administration to End Private Medicare Drug Plan Subsidies
  • NPRA Warns of Pancreatitis Risk With Diabetes and Weight Loss Drugs (archyde.com)

Related

Evlarco, ezetimibe, Icotyde, lerodalcibep, Lynavoy, Lyrokaul, obicetrapib, ranibizumab, Susvimo, Ubeslo

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service